237
Views
2
CrossRef citations to date
0
Altmetric
Short Communication

Hepatitis C Virus (HCV) Viremia in Patients with Indeterminate Second-Generation HCV Recombinant Immunoblot Assay

, , , , &
Pages 83-85 | Published online: 15 Apr 2014
 

ABSTRACT

Positivity of recombinant immunoblot assay (RIBA 2) for detection of antibodies to Hepatitis C virus (anti-HCV) is usually associated with HCV viremia. The significance of an indeterminate RIBA result defined by reactivity to only one HCV antigen is more problematic. The aim of this study was to determine: 1) the prevalence of RIBA indeterminate subjects, and 2) the correlation between RIBA indeterminate result and viremia according to the presence of normal or increased alanine aminotransferase (ALT) levels. In all RIBA 2 indeterminate subjects HCV RNA was detected by reverse transcription polymerase chain reaction (RT-PCR), and serum ALT was measured. An indeterminate RIBA 2 was found in 30 (15.15%) of subjects. Comparing the distribution of individual reactivity to HCV antigens (c22-3, c33c, c100–3 and 5–1–1) we found the reactivity to c22–3 to be the most frequent (p<0.001). Of 30 RIBA indeterminate subjects HCV RNA was detected in 19 (63,3%) of which 15 (78,9%) were anti-c22-3-positive. Analysing of RNA positivity according to ALT levels, we found that all the patients with elevated ALT and 15.3% of those with normal ALT levels were HCV RNA positive. We have found a significant correlation between viremia and elevated ALT levels. This study demonstrated that HCV viremia was frequent in subjects with indeterminate RIBA, especially in those with increased ALT levels.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.